This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PharmaVentures Acts As Exclusive Advisor On The Sale Of A Majority Stake In DoĿu Tip, A Turkish Diagnostic Imaging Services Company,to Techno Group Investment Holdings, A Gulf Capital Portfolio Company

OXFORD, England, April 11, 2013 /PRNewswire/ --

PharmaVentures is pleased to announce that Techno Group Investment Holdings, a portfolio company of Gulf Capital, has acquired 100% of Doğu Tip, a Turkish provider of outsourced diagnostic imaging services, with a subsequent allocation of 25% incentive shares to the management.

PharmaVentures, a leading life science and healthcare advisory firm, was advisor to Doğu Tip and its shareholders.

Techno Group is the leading provider of diagnostic imaging services in the MENA region.  Gulf Capital is a leading MENA private equity firm based in Abu Dhabi with close to $2 billion in assets under management.

PharmaVentures' CEO, Dr Fintan Walton said, "This deal marks another step in our increased success in M&A generally and in cross-border Emerging Market deals specifically.  We are delighted to have worked on this transaction to deliver a successful outcome on behalf of our client".

Ping Shek, who was PharmaVentures' lead advisor on the deal said, " Turkey is a key regional hub with a large growing healthcare market.  We envisage a continuing high level of investment activity there, especially since the government has recently passed new regulations encouraging foreign investment in its healthcare sector".

Established in 1992, PharmaVentures has worked on over 600 advisory assignments for clients from top global pharmaceutical and healthcare groups to fast growing biotech companies.  In recent years, it has been increasingly active in M&A, working on assignments worldwide.

About PharmaVentures

PharmaVentures is a premier transaction advisory firm; a world leader in partnering, M&A deals and strategic alliances.  Our unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes us uniquely placed to support your business in all aspects of deal making and strategic planning.  PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs